4D Molecular Therapeutics (Nasdaq: FDMT) announced that the first patients have been enrolled in its 4SIGHT Phase 3 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE